AI assistant
Sending…
Q32 Bio Inc. — Director's Dealing 2018
Mar 27, 2018
34891_dirs_2018-03-27_e06397fb-c243-4b26-89da-1603bf4bcfe7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2018-03-27
Reporting Person: Seymour Albert (Chief Scientific Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 228250 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Employee Stock Option | $6.64 | 2027-12-07 | Common Stock (76417) | Direct |
Footnotes
F1: The option vests and becomes exercisable upon the Reporting Person's completion of each full month of service after January 1, 2018.
More from Q32 Bio Inc.
Capital/Financing Update
2026
May 27
Interim / Quarterly Report
2026
May 5
Earnings Release
2026
May 5
Annual Report
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 30
Capital/Financing Update
2026
Apr 24
Director's Dealing
2026
Mar 21
Director's Dealing
2026
Mar 21
Director's Dealing
2026
Mar 21
Director's Dealing
2026
Feb 27